ArticleMolecular therapy : the journal of the American Society of Gene Therapy2009
Lentiviral vectors transduce proliferating dendritic cell precursors leading to persistent antigen presentation and immunization.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 46 citations in OpenAlex.
- Editing T cell repertoire by thymic epithelial cell-directed gene transfer abrogates risk of type 1 diabetes development.Molecular therapy. Methods & clinical development · 2022Article
- Brain cross-protection against SARS-CoV-2 variants by a lentiviral vaccine in new transgenic mice.EMBO molecular medicine · 2021Article
- Dendritic cell-targeted lentiviral vector immunization uses pseudotransduction and DNA-mediated STING and cGAS activation.Science immunology · 2017Article
- Dendritic Cells Cross-Present Immunogenic Lentivector-Encoded Antigen from Transduced Cells to Prime Functional T Cell Immunity.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Article
- Tissue-resident dendritic cells and diseases involving dendritic cell malfunction.International immunopharmacology · 2016Review
- 4-1BB ligand activates bystander dendritic cells to enhance immunization in trans.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Immunogenicity of targeted lentivectors.Oncotarget · 2014Article
- Vaccination with lentiviral vector expressing the nfa1 gene confers a protective immune response to mice infected with Naegleria fowleri.Clinical and vaccine immunology : CVI · 2013Article
- Patients with cystic fibrosis have inducible IL-17+IL-22+ memory cells in lung draining lymph nodes.The Journal of allergy and clinical immunology · 2013Article
- Dendritic cell modification as a route to inhibiting corneal graft rejection by the indirect pathway of allorecognition.European journal of immunology · 2013Article
- Induction of broadly neutralising HCV antibodies in mice by integration-deficient lentiviral vector-based pseudotyped particles.PloS one · 2013Article
- Article
- Article
- Targeting lentiviral vectors for cancer immunotherapy.Current cancer therapy reviews · 2011Article
- Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies.Cancer immunology, immunotherapy : CII · 2011Review
- Immunization delivered by lentiviral vectors for cancer and infectious diseases.Immunological reviews · 2011Review
- HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7.Journal of virology · 2010Article
- Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized usingOncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lentiviral vectors (LVs) are tools for in vivo gene delivery, to correct genetic defects or to deliver antigens for vaccination. It was reported that systemic injection of LVs in mice transduced cells in liver and spleen. Here we describe the reasons for, and consequences of, persistent gene expression in spleen. After 5 days of intravenous injection, a green fluorescence protein (GFP)-expressing LV was detected in lymphocytes, macrophages and all subsets of dendritic cells (DCs) in spleen. In the case of macrophages and DCs, the percentage of transduced cells increased between 5 and 30 days after injection. We used bromodeoxyuridine (BrdU) incorporation to show that the macrophages were largely nondividing, whereas the transduced DCs arose from dividing precursor cells and could be detected in spleen 2 months after injection. Expression of ovalbumin (OVA) in the LV reduced the number of transduced DCs in spleen after 30 days. However, the remaining transduced cells stimulated proliferation and activation of OVA-specific CD8(+) T cells transferred 2 months after LV injection. The mice also maintained cytolytic activity against OVA-pulsed targets. These results show that LVs transduce DC precursors, which maintain transduced DCs in spleen for at least 2 months, leading to prolonged antigen presentation and effective T-cell memory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.